MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/gox.0000000000007782

Медицинская библиотека · Plastic and reconstructive surgery. Global open · 2026

The State of Posttransplant Malignancies in Vascularized Composite Allotransplantation.

Gursky Alexis K, Horn Allison N, Wyatt Hailey P, Chinta Sachin R, Shah Alay R, Gelb Bruce E, Ceradini Daniel J, Rodriguez Eduardo D

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Vascularized composite allotransplantation (VCA) restores complex defects when conventional reconstruction is not feasible. However, lifelong immunosuppression introduces substantial risks, including posttransplant malignancies. This study aims to characterize the incidence, timing, management, and outcomes of posttransplant malignancies in VCA recipients to inform future surveillance and management guidelines.

METHODS

A systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines using PubMed, Scopus, Web of Science, and Cochrane. Eligible studies included patients who underwent VCA and developed a subsequent malignancy. Collected data included demographics, transplant and malignancy details, and survival.

RESULTS

Fifteen studies comprising 15 unique VCA recipients were included. Transplants involved the face (37.5%), upper extremity (37.5%), scalp (12.5%), lower extremity (6.25%), and abdominal wall (6.25%). Median time to first malignancy was 1.89 years posttransplant. Across all cases, 24 malignancies were reported, most commonly nonmelanoma skin cancer (60%) and posttransplant lymphoproliferative disorder (33%). Notably, 85% of skin cancers developed at nonallograft sites. Overall survival was 53.3%. All patients with skin cancer alone survived, whereas posttransplant lymphoproliferative disorder carried a 50% mortality rate. Median time from malignancy to death was 5.5 years, and from transplant to death, 10.1 years.

CONCLUSIONS

Recipients of VCA demonstrate increased malignancy risk, particularly nonmelanoma skin cancers and lymphoma, with a typical onset of 2 years posttransplant. Dermatologic surveillance focusing on native skin, Epstein-Barr virus viral load monitoring in high-risk recipients, and regular follow-up are essential and may aid early detection.

Для цитирования: Gursky Alexis K, Horn Allison N, Wyatt Hailey P, Chinta Sachin R, Shah Alay R, Gelb Bruce E, Ceradini Daniel J, Rodriguez Eduardo D. The State of Posttransplant Malignancies in Vascularized Composite Allotransplantation.. Plastic and reconstructive surgery. Global open. 2026. DOI: 10.1097/gox.0000000000007782.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.